Ending the Sun’s Monopoly: The Future of Stellarator Fusion - Brian Berzin, CEO, Thea Energy

Send us Fan MailInside a fusion reactor, you’re not just creating a star—you’re building a machine that has to survive one. Temperatures hotter than the sun, relentless neutron bombardment… and materials that slowly destroy themselves from the inside out.Daniel Clark is a nuclear engineer and fusion energy expert working at the forefront of turning fusion from a scientific pursuit into a practical energy solution.Daniel is currently Director of Nuclear and Fuel Cycle Engineering at Type One Energy Group ( https://typeoneenergy.com/ ), where he leads critical efforts in breeder blanket and first wall design, as well as the tritium fuel cycle - core systems that will ultimately determine whether fusion reactors can operate sustainably at scale.Prior to joining the private sector, Daniel spent nearly eight years at the U.S. Department of Energy Office of Science, where he managed the Fusion Materials Research Portfolio. During that time, he helped launch major national initiatives, including the Material Plasma Exposure eXperiment at Oak Ridge National Laboratory, the INFUSE public-private partnership program, and the Fusion Prototypic Neutron Source.With degrees in nuclear engineering from Texas A&M University and University of Tennessee, Knoxville, Daniel brings a rare combination of deep technical expertise, federal policy insight, and commercialization experience—making him one of the key voices shaping the future of fusion energy.#FusionEnergy #NuclearFusion #CleanEnergy #FutureOfEnergy #EnergyInnovation #DeepTech #ClimateTech #Physics #NuclearEngineering #MaterialsScience #EnergyTransition #Tritium #SciencePodcast #TechPodcast #HardTech #Engineering #Innovation #FusionPower #StartupEnergy #BigScience #NextGenEnergy #AdvancedMaterials #EnergyFuture #BreakthroughScience #ClimateSolutionsSupport the show

Send us Fan MailWhat if the reason we haven’t explored deep space isn’t because we can’t… but because our engines are fundamentally too slow?Richard Dinan is Founder and CEO of Pulsar Fusion ( https://pulsarfusion.com/ ) and one of the few entrepreneurs in the world not trying to bring fusion power to Earth… but to space.While most fusion startups are focused on powering cities, Richard is building engines designed to power spacecraft—fusion propulsion systems that could dramatically cut travel times to Mars, unlock missions to Saturn’s moon Titan, and fundamentally reshape how we explore the solar system.Pulsar’s flagship efforts—including its Dual Direct Fusion Drive and the Sunbird program—aim to combine high-thrust propulsion with onboard power generation, a combination that could enable entirely new classes of deep-space missions. The company is now working with the United Kingdom Atomic Energy Authority on advanced neutron shielding and activation modeling—critical challenges for making fusion viable and safe in space.Backed by the UK Space Agency and collaborating with the European Space Agency, Pulsar is positioning itself at the center of a new space race—one where the bottleneck isn’t getting off Earth… but moving once you’re already out there.On this episode we talk about why space might be the first place fusion actually works, what it takes to build engines that can survive neutron bombardment, and whether radically faster travel could open up the outer solar system within our lifetime.#fusionenergy #spacetechnology #spaceexploration #marsmission #deepspace #futureofspace #nuclearfusion #fusionpropulsion #spacex #nasa #spaceinnovation #aerospace #futuretech #pulsarfusion #richarddinan #sciencepodcast #techpodcast #engineering #physics #spacefuture #interplanetary #spaceindustry #nextgentech #hardtech #innovation #elonmusk #spaceeconomy #ukspace #europespace #austintechSupport the show

Send us Fan MailWhat if we could build a fusion reactor that runs continuously—without the instability issues that have plagued the field for years?Brian Berzin is the Co-Founder and CEO of Thea Energy ( https://thea.energy/ ), a next-generation fusion company focused on advancing stellarator technology—one of the most promising but historically underexplored approaches to magnetic confinement fusion.Brian brings a unique combination of deep technical and financial expertise, with a background spanning electrical engineering, venture capital, private equity, and investment banking. Prior to founding Thea Energy, Brian served as Vice President of Strategy at General Fusion, where he helped shape commercialization strategy and led engagement with global capital markets during a pivotal period for privately funded fusion.At Thea Energy, Brian is leading efforts to “end the sun’s monopoly on fusion energy” by leveraging breakthroughs in high-temperature superconducting materials and advanced computational design to build more stable and scalable fusion systems. In 2023, the company was selected as one of a small group of awardees in the U.S. Department of Energy’s milestone-based fusion development program.Brian holds dual degrees in Electrical Engineering and Finance from Lehigh University, reflecting the interdisciplinary mindset he now applies to one of the hardest engineering challenges in the world: making fusion power a commercial reality.#fusionenergy #fusion #cleanenergy #nuclearfusion #stellarator #tokamak #science #energy #futureofenergy #deeptech #climatechange #renewableenergy #hightech #engineering #superconductors #HTS #fusionpower #energytransition #cleantech #futuretech #startup #innovation #sciencepodcast #energyindependence #decarbonization #physics #bigideasSupport the show

Send us Fan MailImagine treating back pain not with surgery, not with opioids—but by using your own stem cells to repair the damage at its source.Lance Alstodt is President, CEO, and Chairman of BioRestorative Therapies, Inc. ( https://biorestorative.com/ ), a publicly traded regenerative medicine company focused on developing stem cell-based therapies to treat highly prevalent conditions, including chronic lower back pain and metabolic disorders.With more than 25 years of experience across healthcare investment banking, medical technology, and company building, Lance brings a unique perspective at the intersection of science and capital markets. Prior to joining BioRestorative, he was the founder and CEO of MedVest Consulting, advising healthcare companies on growth strategy, M&A, and capital formation.Earlier in his career, Lance held senior leadership roles at firms including Leerink Partners, Oppenheimer & Co., Bank of America Merrill Lynch, and JPMorgan Chase & Co., where he specialized in healthcare and medical technology transactions.At BioRestorative, Lance is leading the development of innovative cell therapies such as BRTX-100, an autologous mesenchymal stem cell therapy currently in Phase 2 trials for chronic lumbar disc disease, aiming to offer a non-opioid, non-surgical solution to one of the most widespread causes of disability worldwide.#StemCells #RegenerativeMedicine #BackPainRelief #Biotech #HealthcareInnovation #MedicalBreakthrough #ChronicPain #BioTech #FutureOfMedicine #StemCellTherapy #DegenerativeDiscDisease #PainManagement #HealthTech #BiotechStocks #Longevity #MedicalInnovation #CellTherapy #NonSurgicalTreatment #OpioidCrisis #SciencePodcast #HealthcareRevolutionSupport the show

Send us Fan MailWe’re living through a golden age of rare disease breakthroughs—but for many patients, the hardest part begins after the drug is approved.Today we’re joined by two leaders from the multinational biopharmaceutical company UCB ( https://www.ucb.com/ ) who are helping reshape how the rare disease community thinks about what happens after a therapy is approved—because for many families, approval is just the beginning of the journey.Dr. Kim Moran, Ph.D. is Senior Vice President and Head of U.S. Rare Diseases at UCB ( https://www.ucb-usa.com/UCB-in-the-U-S/U-S-Leadership-Team/Kim-Moran ). Dr. Moran leads the company’s U.S. rare disease portfolio strategy and commercial organization, integrating clinical, regulatory, operational, and digital capabilities to bring therapies to patients with devastating and often ultra-rare conditions. Trained as a neuroscientist with a PhD from NYU and an Executive MBA from INSEAD, she has spent nearly two decades at UCB translating patient insights into real-world solutions—from epilepsy portfolio strategy to leading the recent FDA approvals and launches of two major rare disease assets. Dr. Moran is widely recognized for her leadership in the industry, including honors from the Healthcare Businesswomen’s Association and Medical Marketing + Media, and she remains deeply focused on ensuring scientific breakthroughs actually translate into meaningful impact for patients and families.Brad Chapman is Head of U.S. Epilepsy and Rare Syndromes at UCB ( https://www.ucb-usa.com/UCB-in-the-U-S/U-S-Leadership-Team/Brad-Chapman ). Mr. Chapman oversees one of the deepest portfolios of anti-seizure therapies in the industry, including BRIVIACT, NAYZILAM, and FINTEPLA, while leading nationwide teams focused on connecting patients with both treatment and support systems. Over more than 15 years with UCB, Mr. Chapman has helped pioneer new go-to-market models in neurology that move decision-making closer to patients and providers, strengthen partnerships with the epilepsy community, and rethink how pharmaceutical organizations deliver value “beyond the pill.”Together, Dr. Moran and Mr. Chapman sit at the intersection of scientific innovation, patient access, and community infrastructure, and they’re helping answer a critical question in rare disease: How do we make sure life-changing therapies actually reach—and work for—the patients who need them most?Important Episode Link - Caring for Adults with Rare Epilepsy -https://www.ucb-usa.com/sites/default/files/2024-06/UCBCAREBinder.pdf#RareDisease #UltraRareDisease #Epilepsy #CDKL5 #DravetSyndrome #RareEpilepsy #Biotech #Pharma #DrugDevelopment #PrecisionMedicine #Geroscience #HealthcareInnovation #PatientAccess #CaregiverSupport #MedicalInnovation #Neuroscience #MitochondrialDisease #TK2Deficiency #ClinicalTrials #LifeSciences #Biopharma #HealthPolicy #FutureOfMedicine #PatientCare #InnovationSupport the show

Send us Fan MailWhether it’s a battlefield, a construction site, or a farm, the challenge is the same: how do you turn massive amounts of visual data into fast, accurate decisions? Increasingly, the answer is autonomous systems. transforming how we see the world—turning raw imagery into decisions at unprecedented speed.Bill Irby is CEO and Board Member of EagleNXT ( https://eaglenxt.com/ ), a leading provider of full-stack drone, sensor, and software solutions serving both commercial and government customers worldwide.Bill brings more than 25 years of leadership experience across the unmanned systems and defense technology landscape, spanning ISR (Intelligence, Surveillance, and Reconnaissance) platforms, communications systems, and advanced autonomy. Prior to EagleNXT, Bill held senior executive roles across some of the most important defense companies in the world, including serving as President of Reconnaissance Mission Systems at L3Harris Technologies, where he led a $1.5 billion portfolio supporting some of the U.S. military’s most critical airborne intelligence platforms.Bill also served as Senior Vice President and General Manager of Unmanned Systems at Textron Systems, overseeing globally deployed UAV and unmanned maritime systems, and held multiple leadership roles at Northrop Grumman, focusing on C4ISR (Command, Control, Communications, Computers, Intelligence, Surveillance, and Reconnaissance) and tactical communications.Earlier in his career, Bill served as a Combat Engineer in the United States Marine Corps, leading missions across the globe.In addition to his operational leadership, Bill has played a key role in shaping the unmanned systems ecosystem serving as Chairman of the Board of AUVSI ( Association for Uncrewed Vehicle Systems International - https://www.auvsi.org/ ), advocating for the safe integration and advancement of autonomous technologies.Bill is a graduate of the United States Naval Academy, holds a master’s degree from Johns Hopkins University, and completed executive education at Harvard Business School.#DefenseTech #DroneWarfare #AutonomousSystems #MilitaryDrones #ISR #ArtificialIntelligence #FutureOfWar #UncrewedSystems #Aerospace #NationalSecurity #Robotics #AI #MilitaryTechnology #Innovation #TechPodcast #EmergingTech #BattlefieldTechnology #Surveillance #Geopolitics #StartupDefenseSupport the show

Send us Fan MailPreventing transplant loss doesn’t just save organs—it could eliminate hospitalizations, reduce lifelong medications, and transform millions of lives.Dr. Janine Gaiha-Rohrbach, Ph.D. is a globally recognized leader in immunology and medical strategy, currently serving as Head of Global Medical Immunology at Biogen ( https://www.biogen.com/ ). With a PhD in Immunology and Virology from the University Hospital of Berne and extensive postdoctoral research at the Ragon Institute of Mass General Brigham, MIT, and Harvard, Dr. Gaiha-Rohrbach has dedicated her career to translating complex scientific advances into high-impact patient care.Throughout her career, Dr. Gaiha-Rohrbach has driven innovation across diverse therapeutic areas, including HIV, hepatitis, NASH, and specialized immunology, leading multiple new product launches and shaping global strategies to expand patient access.At Biogen, Dr. Gaiha-Rohrbach now focuses on advancing therapies in immunology with an emphasis on areas of high unmet need, including the evolving field of kidney transplantation.On today’s episode, we’ll explore the future of kidney transplant care, the limitations of current treatments for antibody-mediated rejection, and how emerging therapies targeting the immune system are poised to transform patient outcomes.#KidneyTransplant #TransplantInnovation #Biogen #Immunology #AntibodyMediatedRejection #AMR #CD38 #Felzartamab #OrganTransplant #HealthcareInnovation #Biotech #DrugDevelopment #PrecisionMedicine #Nephrology #ChronicKidneyDisease #MedicalBreakthrough #FutureOfMedicine #Immunotherapy #TransplantMedicine #LifeSavingScience #Podcast #HealthcarePodcast #BiotechPodcast #SciencePodcastSupport the show

Send us Fan MailPharma has spent decades building a graveyard of failed drugs — but hidden inside that data may be treatments that actually worked… for someone.Vin Singh is Founder and CEO of BullFrog AI ( https://bullfrogai.com/ ), a company working at the intersection of machine learning, causal modeling, and drug development.BullFrog is focused on a fundamental problem in biopharma — not just how to analyze increasingly large datasets, but how to extract meaningful cause-and-effect relationships from them. Their platform integrates data preparation, analysis, and network-based modeling to help research teams better understand biological mechanisms, identify patient subgroups, and improve clinical trial design.Vin brings a deep mix of technical, operational, and entrepreneurial experience to this challenge. Prior to founding BullFrog, he held leadership roles across the life sciences ecosystem, including serving as Global Director of the Cell Therapy Business at Thermo Fisher Scientific, where he oversaw services supporting clinical and commercial-stage therapies. He also founded and led Next Healthcare, a company focused on adult stem cell and skin cell banking, and was an early co-founder at MaxCyte, helping build foundational technologies in cell engineering.In addition to his operating roles, Vin has been active in the innovation ecosystem as a Mentor in Residence at Johns Hopkins Technology Ventures.Vin holds an MBA in Finance from Johns Hopkins University, a Master’s in Biomedical Engineering from Rensselaer Polytechnic Institute, and a Bachelor’s in Electrical Engineering from Rutgers University — a background that spans engineering, biology, and business.#CausalAI #DrugDevelopment #Biotech #ClinicalTrials #PrecisionMedicine #AIinHealthcare #PharmaInnovation #FailedDrugs #OncologyResearch #PancreaticCancer #FutureOfMedicine #MachineLearning #Biopharma #TranslationalMedicine #DigitalHealth #MedicalInnovation #DataScience #ClinicalResearch #AIinBiotech #HealthcareInnovationSupport the show

Send us Fan MailBone marrow transplants have always depended on finding the right donor at the right time. But what if bone marrow could be stored, shipped, and used on demand—just like a drug? That’s exactly what Ossium Health is now showing in human clinical data.Kevin Caldwell is the Co-Founder, CEO, and President of Ossium Health ( https://ossiumhealth.com/ ), a clinical-stage bioengineering company pioneering off-the-shelf, cryopreserved bone marrow therapies derived from deceased organ donors.Under Kevin’s leadership, Ossium has developed a novel platform designed to solve one of the most persistent challenges in transplantation medicine: timely access to compatible bone marrow for patients with life-threatening hematologic malignancies such as Acute Myeloid Leukemia. The company’s approach enables on-demand delivery of viable marrow cells, bypassing the logistical and biological constraints of traditional donor matching and scheduling.Since its founding, Kevin has scaled Ossium from an early-stage startup into a clinical-stage company with a robust network of over 50 strategic partnerships across supply, clinical development, and commercial channels. He has led multiple financings and secured a landmark contract with the Biomedical Advanced Research and Development Authority, validating Ossium’s relevance to national health preparedness and biomanufacturing resilience.Most recently, Kevin has overseen the company’s transition into human clinical validation, including first-in-human data from the PRESERVE I trial, real-world use cases in transplant rescue scenarios, and peer-reviewed publication of its GMP-based manufacturing platform and early outcomes.Prior to founding Ossium, Kevin was an Engagement Manager at McKinsey & Company, advising biotech and healthcare companies on strategy, M&A, and restructuring. Earlier, he worked in quantitative research at Bridgewater Associates. He holds degrees in Physics and Economics from MIT and a JD from Harvard Law School.#Biotech #BoneMarrowTransplant #StemCells #CancerTreatment #Leukemia #AML #CellTherapy #RegenerativeMedicine #Biotechnology #FutureOfMedicine #HealthcareInnovation #MedicalBreakthrough #Immunotherapy #TransplantMedicine #Cryopreservation #LongevityScience #Bioengineering #StartupScience #OnDemandMedicine #PrecisionMedicine #ClinicalTrials #Biopharma #DeepTech #LifeSciences #HealthcareDisruptionSupport the show

Send us Fan MailThere’s an entire medical specialty, Physiatry, dedicated not to treating disease - but to helping patients regain their lives. And most people have never heard of it.Dr. Michael Yochelson is a Physiatrist and a nationally recognized leader in rehabilitation medicine and brain injury care ( https://shepherd.org/staff-directory/michael-yochelson/ ).Dr. Yochelson serves as the Chief Medical Officer at Shepherd Center, one of the top hospitals in the United States for spinal cord and brain injury rehabilitation. He is also an Adjunct Professor at Emory University School of Medicine ( https://med.emory.edu/directory/profile/?u=MYOCHEL ).Board-certified in both neurology and physical medicine & rehabilitation, Dr. Yochelson has spent decades at the forefront of helping patients recover from some of the most complex neurological injuries. Prior to Shepherd Center, he held major leadership roles at MedStar National Rehabilitation Network and Georgetown University, where he also founded and led a Brain Injury Medicine Fellowship program.Earlier in his career, Dr. Yochelson served for over a decade in the United States Navy, including leadership roles in neurology and rehabilitation medicine.In addition to his clinical and academic work, Dr. Yochelson serves on the Board of Governors of the American Academy of Physical Medicine and Rehabilitation ( https://www.aapmr.org/ ), where he chairs the Inclusion and Engagement Committee, helping shape the future of a specialty dedicated not just to treating disease—but restoring function, independence, and quality of life.Important Episode Link - Understanding Spasticity: A Simple Guide to Symptoms, Treatment, and Getting Better - https://www.aapmr.org/resources/AAPMR_Spasticity_Patient_Journey.html#Physiatry #RehabilitationMedicine #AAPMR #Neurorehabilitation #BrainInjury #StrokeRecovery #SpinalCordInjury #Mobility #Function #QualityOfLife #Neuroplasticity #RecoveryScience #FutureOfMedicine #HealthcareInnovation #PatientRecovery #DisabilityCare #HumanPerformance #Longevity #MedicinePodcast #HealthPodcast #SciencePodcast #ClinicalInnovation #MedicalEducation #RestoreFunctionSupport the show